Christine Campo Alewine, M.D., Ph.D.

Lasker Clinical Research Scholar

Laboratory of Molecular Biology


Building 37, Room 5116B
Bethesda, MD 20892


Research Topics

Pancreatic cancer is a devastating disease that kills more than 45,000 Americans each year. About 10% of patients survive five years or more after diagnosis because the disease metastasizes very early in its development and is difficult to treat. More effective and tolerable systemic therapies are needed for treatment of pancreatic cancer patients.

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreas cancer. PDAC has a dense tumor microenvironment that contains cancer-associated fibroblasts that can both support and restrain cancer cell growth. The therapeutic cytotoxin ProAgio remodels the tumor microenvironment by targeting and killing cells that express integrin alpha-v beta-3. These include cancer-associated fibroblasts, macrophages and endothelial cells as well as some cancer cells. We are currently testing this first-in-class drug in the clinic. In the laboratory we are working to: 1) identify effective combination therapies that can enhance penetration of biologic type therapeutics to PDAC and 2) understand molecular signals that contribute to PDAC peritoneal metastasis, one of the most common sites for PDAC to spread.

Rarer exocrine tumors of the pancreas are typically treated with standard therapies optimized for PDAC. We are interested in learning more about these tumors so that better treatments can be identified, and are actively recruiting patients with these tumor types: 1) Adenosquamous carcinoma of the pancreas (ASCP) is a highly aggressive variant of PDAC that is driven by the Myc oncogene. Minnelide is an oral drug that reduces Myc expression and inhibits growth of ASCP in pre-clinical models. We are currently testing the anti-tumor activity of Minnelide in a Phase II trial specific for patients with ASCP. 2) Pancreatic Acinar Cell Carcinoma (PACC) is an ultra-rare tumor of the pancreas with distinct genetic and pathologic features from PDAC. We are interested in developing pre-clinical models of PACC that will permit detailed study of the tumor’s molecular landscape. Patients with PACC and ASCP are encouraged to participate in the Rare Solid Tumor Natural History study to help us better understand the clinical course of PACC. Travel to Bethesda is not required to participate in the Natural History study.


Dr. Alewine received her M.D. and Ph.D. from the University of Maryland School of Medicine. She completed internal medicine residency in the Osler Medical Training Program at Johns Hopkins Hospital followed by clinical fellowship in Medical Oncology at the National Cancer Institute. She joined the Laboratory of Molecular Biology as an Assistant Clinical Investigator through the support of the Clinical Investigator Development program in 2014 and became a tenure-track investigator through the NIH Lasker Scholar program in 2016.

Selected Publications

  1. Hagerty BL, Pegna GJ, Xu J, Tai CH, Alewine C. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. Biomolecules. 2020;10(7).
  2. Alewine C, Ahmad M, Peer CJ, Hu ZI, Lee MJ, Yuno A, Kindrick JD, Thomas A, Steinberg SM, Trepel JB, Figg WD, Hassan R, Pastan I. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2020;26(4):828-836.
  3. Avula LR, Rudloff M, El-Behaedi S, Arons D, Albalawy R, Chen X, Zhang X, Alewine C. Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases. Mol Cancer Res. 2020;18(2):229-239.
  4. El-Behaedi S, Landsman R, Rudloff M, Kolyvas E, Albalawy R, Zhang X, Bera T, Collins K, Kozlov S, Alewine C. Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. Toxins (Basel). 2018;10(11).
  5. Kolyvas E, Rudloff M, Poruchynsky M, Landsman R, Hollevoet K, Venzon D, Alewine C. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes. Oncotarget. 2017;8(6):9189-9199.

Related Scientific Focus Areas

This page was last updated on Wednesday, May 1, 2024